Market Composite

BIOC - Biocept Inc

$3.99

0.04(1.01%)5:50:18 PM 12/1/2021

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.

Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary

Related Peers

EXAS-1.40%

MYGN-4.50%

VCYT0.10%

Stock news

11/22/2021BIOC

Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression

AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services. This novel test is highly sensitive and specific, and can quantify a patient's SARS-CoV-2 viral load to determine the active infection level.

11/22/2021BIOC

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

SAN DIEGO, November 22, 2021--Biocept launches combined COVID-19 and influenza test to help patients and caregivers determine treatment decisions during peak flu season.

11/22/2021BIOC

Biocept launches combined COVID-19 and influenza test

11/18/2021BIOC

CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer

SAN DIEGO, November 18, 2021--Case series shows Biocept's CNSide assay helps monitor treatment response and detects actionable biomarkers in patients with metastatic breast cancer.

11/15/2021BIOC

Biocept Reports Third Quarter 2021 Financial Results

SAN DIEGO, November 15, 2021--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.

11/16/2021BIOC

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2021 Results - Earnings Call Transcript

11/15/2021BIOC

Biocept EPS misses by $0.04, beats on revenue

11/9/2021BIOC

Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations

SAN DIEGO, November 09, 2021--Published abstract shows Biocept's Switch-Blocker technology increases the sensitivity of liquid biopsy assays for detecting rare cancer mutations.

11/8/2021BIOC

Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021

SAN DIEGO, November 08, 2021--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021. The Company will host an investor conference call to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

10/6/2021BIOC

Biocept to Present at the LD Micro Main Event on October 13

SAN DIEGO, October 06, 2021--Biocept to present at LD Micro Main Event

scroll to load more

Related Topics

Related Peers

Stock news